EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Hepatitis B Virus NAT Positive Donors in Non‐Hepatic Organ Transplant: Quantifying Viral Loads to Optimize Recipient Risk Stratification and Management in the Prevention of Donor‐Derived Infection

Patrick C K Tam iD, Goni Katz-Greenberg iD, Cameron R Wolfe iD, Kristen Lott, Carl L Berg, Adam D DeVore iD, John M Reynolds, Jennifer L Saullo

Clinical Transplantation · 2025-07 · 39 (7)

DOI: 10.1111/ctr.70236 ↗

At a glance

Journal article in Clinical Transplantation, published online on 2025-07-23. Written by Patrick C K Tam and 7 co-authors. Institution: Division of Infectious Diseases, Duke University School of Medicine, Durham, North Carolina, USA. Major MEDLINE topics: Hepatitis B virus, Tissue Donors, Hepatitis B, Nucleic Acid Amplification Techniques. Cited 5 times so far (Crossref); 36 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Transplantation is one of the few life‐saving therapies for patients with end‐stage organ disease, yet organ availability remains restrictive. Expanding donors to include those with hepatitis B virus (HBV) infection, incorporating HBV nucleic acid amplification testing (NAT) positive donors, could improve organ access. However, the risk of donor‐derived HBV transmission and recipient management of organs transplanted from HBV NAT‐positive donors, particularly in thoracic organ recipients, is limited. We conducted a single‐center retrospective study to assess the safety and outcomes in recipients of non‐hepatic organ transplants from HBV NAT‐positive donors. Over a 4.5‐year period, 25 transplant recipients, including 16 thoracic organ recipients, received organs from 22 unique, qualitative HBV NAT‐positive donors. All recipients were HBV surface antibody‐positive prior to transplant. Quantitative NAT was performed in 20/22 (91%) donors with values ranging from 0 to 1 280 000 IU/mL; 8/22 (36%) donors had HBV NAT values that were undetected or below the lower limit of quantification. All recipients were administered HBV immunoglobulin (HBIG) and received HBV active antiviral therapy post‐transplant. Recipients were followed post‐transplant for a median of 250 days (IQR: 169–467 days). No recipients developed de novo HBV infection characterized by HBV surface antigen (HBsAg) seroconversion, quantifiable HBV NAT detection, or sustained HBV core antibody (HbcAb) seroconversion post‐transplant. Similarly, no recipient developed liver dysfunction or died due to HBV infection. Quantifying HBV from NAT‐positive donors may better inform the risk of donor‐derived infection in recipients, and the use of these organs incorporating a multimodal prevention strategy could safely increase the donor pool.

Subjects

MeSH terms (MEDLINE)

Hepatitis B virusTissue DonorsHepatitis BNucleic Acid Amplification TechniquesViral LoadOrgan TransplantationDNA, ViralHumansMaleRetrospective StudiesFemaleMiddle AgedFollow-Up StudiesPrognosisAdultRisk FactorsTransplant RecipientsRisk AssessmentGraft SurvivalDonor Selection

Author keywords

Hepatitis B virusdonor‐derived hepatitisentecavirimmunoglobulinkidney transplantationthoracic transplantation

Substances

DNA, Viral

Authors and institutions

  • Division of Infectious Diseases, Duke University School of Medicine, Durham, North Carolina, USA.
  • College of Medicine and Public Health, Flinders University, Adelaide, Australia.
  • Division of Nephrology, Duke University School of Medicine, Durham, North Carolina, USA.
  • Duke Transplant Center, Durham, North Carolina, USA.
  • Division of Gastroenterology and Hepatology, Duke University School of Medicine, Durham, North Carolina, USA.
  • Division of Cardiology, Duke University School of Medicine, Durham, North Carolina, USA.

ORCID profiles: Patrick C K Tam, Goni Katz-Greenberg, Cameron R Wolfe, Adam D DeVore

Cite

APA

Tam, P. C. K., Katz-Greenberg, G., Wolfe, C. R., Lott, K., Berg, C. L., DeVore, A. D., Reynolds, J. M., & Saullo, J. L. (2025). Hepatitis B Virus NAT Positive Donors in Non‐Hepatic Organ Transplant: Quantifying Viral Loads to Optimize Recipient Risk Stratification and Management in the Prevention of Donor‐Derived Infection. Clinical Transplantation, 39(7). https://doi.org/10.1111/ctr.70236

Vancouver

Tam PCK, Katz-Greenberg G, Wolfe CR, Lott K, Berg CL, DeVore AD, et al. Hepatitis B Virus NAT Positive Donors in Non‐Hepatic Organ Transplant: Quantifying Viral Loads to Optimize Recipient Risk Stratification and Management in the Prevention of Donor‐Derived Infection. Clinical Transplantation. 2025;39(7). doi:10.1111/ctr.70236

BibTeX
@article{Tam2025,
  author = {Tam, Patrick C K and Katz-Greenberg, Goni and Wolfe, Cameron R and Lott, Kristen and Berg, Carl L and DeVore, Adam D and Reynolds, John M and Saullo, Jennifer L},
  title = {Hepatitis B Virus NAT Positive Donors in Non‐Hepatic Organ Transplant: Quantifying Viral Loads to Optimize Recipient Risk Stratification and Management in the Prevention of Donor‐Derived Infection},
  journal = {Clinical Transplantation},
  year = {2025},
  volume = {39},
  number = {7},
  doi = {10.1111/ctr.70236}
}
Start for free →